Search

Your search keyword '"Leibaschoff, G."' showing total 9 results
Start Over Author "Leibaschoff, G."
9 results on '"Leibaschoff, G."'

1. Genitourinary syndrome of menopause and the role of biostimulation with non-cross-linked injectable hyaluronic acid plus calcium hydroxyapatite

Author

González, I., Leibaschoff, G., Esposito, C., Cipolla, G., Bader, A., Lotti, T., Tirant, M., Thuong, N., Abdulkader, M. R., Raffaele Rauso, Serafin, D., Vojvodic, A., Zerbinati, N., González, I P, Leibaschoff, G, Esposito, C, Cipolla, G, Bader, A, Lotti, T, Tirant, M, Van Thuong, N, Ramo Abdulkader, M, Rauso, R, Serafin, D, Vojvodic, A, and Zerbinati, N

Subjects
Durapatite, Genitourinary, Menopause, Vulvovaginal atrophy, Humans, Female, Syndrome, Hyaluronic Acid, Female Urogenital Diseases
Published
2019

2. In response to the FDA warning about the use of photomedicine in gynecology

Author

Escribano, J.J. González-Isaza, P. Tserotas, K. Athanasiou, S. Zerbinati, N. Leibaschoff, G. Salvatore, S. Sánchez-Borrego, R.

Abstract

To alert patients and health care providers about the use of energy-based devices to perform a vaginal “rejuvenation,” cosmetic vaginal procedures, or nonsurgical vaginal procedures to treat symptoms related to menopause, urinary incontinence, or sexual function, the US Food and Drug Administration (FDA) has issued a warning about the effectiveness and safety of such devices. We agree with the FDA that certain devices (laser, radiofrequency, etc.) have been marketed inappropriately for uses that are outside of their cleared or approved intended uses. We want to position ourselves in the strict training of professionals so that the indications and techniques are used in the best possible way, knowing that, similar to any medical or surgical technique, the side effects can appear in the short and long term, and should be recognized and remedied. © 2019, Springer-Verlag London Ltd., part of Springer Nature.

Published
2019

3. To the Editor

Author

Gonzalez, P. Salvatore, E. Athanasiou, S. Borrego, R.S. Leibaschoff, G. Tserotas, K. Escribano, J. Zerbinati, N. Awad, D.V.

Published
2019

5. Genitourinary syndrome of menopause and the role of biostimulation with non-cross-linked injectable hyaluronic acid plus calcium hydroxyapatite.

Author

González IP, Leibaschoff G, Esposito C, Cipolla G, Bader A, Lotti T, Tirant M, Van Thuong N, Ramo Abdulkader M, Rauso R, Serafin D, Vojvodic A, and Zerbinati N

Subjects
Female, Humans, Syndrome, Durapatite therapeutic use, Female Urogenital Diseases therapy, Hyaluronic Acid therapeutic use, Menopause
Published
2019
Full Text
View/download PDF

6. In response to the FDA warning about the use of photomedicine in gynecology.

Author

Escribano JJ, González-Isaza P, Tserotas K, Athanasiou S, Zerbinati N, Leibaschoff G, Salvatore S, and Sánchez-Borrego R

Subjects
Humans, Laser Therapy, Practice Guidelines as Topic, Radiofrequency Therapy, United States, Gynecology, Phototherapy, United States Food and Drug Administration
Abstract

To alert patients and health care providers about the use of energy-based devices to perform a vaginal "rejuvenation," cosmetic vaginal procedures, or nonsurgical vaginal procedures to treat symptoms related to menopause, urinary incontinence, or sexual function, the US Food and Drug Administration (FDA) has issued a warning about the effectiveness and safety of such devices. We agree with the FDA that certain devices (laser, radiofrequency, etc.) have been marketed inappropriately for uses that are outside of their cleared or approved intended uses. We want to position ourselves in the strict training of professionals so that the indications and techniques are used in the best possible way, knowing that, similar to any medical or surgical technique, the side effects can appear in the short and long term, and should be recognized and remedied.

Published
2019
Full Text
View/download PDF

7. To the Editor.

Author

Gonzalez P, Salvatore E, Athanasiou S, Borrego RS, Leibaschoff G, Tserotas K, Escribano J, Zerbinati N, and Awad DV

Subjects
Administration, Intravaginal, Atrophy, Female, Humans, Research Design, Vagina
Published
2019
Full Text
View/download PDF

8. To the Editor.

Author

Gonzalez-Isaza P, Sanchez-Borrego R, Escribano J, Zerbinati N, Tserotas K, and Leibaschoff G

Subjects
Female, Humans, Menopause, Syndrome, Vulva, Lasers, Gas
Published
2018
Full Text
View/download PDF

9. Transcutaneous Temperature Controlled Radiofrequency (TTCRF) for the Treatment of Menopausal Vaginal/Genitourinary Symptoms.

Author

Leibaschoff G, Izasa PG, Cardona JL, Miklos JR, and Moore RD

Subjects
Female, Humans, Prospective Studies, Temperature, Treatment Outcome, Urinary Incontinence, Stress etiology, Vaginal Diseases, Hyperthermia, Induced methods, Menopause, Urinary Incontinence, Stress therapy
Abstract

Objective: The aim of this study was to evaluate the effects of non-ablative, monopolar transcutaneous temperature controlled radiofrequency (TTCRF) technology in the treatment of postmenopausal women suffering from genuine stress urinary incontinence (SUI) related to menopause and to evaluate histological changes vaginally associated with the treatment., Materials and Methods: Subjective and objective symptoms of SUI were assessed in study subjects before and after TTCRF, (1 treatment every 30 days, for 3 months; n=10) and compared with the effects of a placebo treatment on a control group of demographically similar women (n =10). SUI was subjectively evaluated with subjective Urogenital Distress Inventory (UDI-6) and with the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-UI SF) before and after TTCRF treatments and objectively with cough stress test. Vaginal health was evaluated with the Vaginal Health Index (VHI) score and visual analogue score (VAS) for dyspareunia and dryness. Punch biopsies were obtained at the urethra-vesical junction in the anterior compartment, before and at the end of the treatment protocol. Basic and histochemical staining methods were used., Results: In subjects suffering SUI, TTCRF treatment was associated with a significant (p<0.01) improvement of ICIQ-SF and UDI-6 scores. Seven of 10 patients (70%) had a negative cough stress test after the treatment protocol. Improvements were maintained up to the 12th week of follow-up. The results were supported by the positive histologic changes seen vaginally in women suffering from postmenopausal vaginal atrophy. TTCRF was well tolerated with no complications reported in study patients., Conclusion: TTCRF treatment in postmenopausal women suffering from SUI showed significant improvement in both objective and subjective symptoms. Vaginal health scores also improved as did VAS for dryness and dyspareunia. We feel these improvements were related to histological changes related to improvement in vaginal atrophy that were not observed in placebo patients.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results